Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 26, 2026, 2:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Peripheral Artery Disease (PAD); Intermittent Claudication Clear all
Completed Not applicable Interventional Results available

DURABILITY™ Iliac Study

NCT01400919
View directory record Official record
Conditions
Peripheral Arterial Disease, Claudication
Interventions
Protégé® EverFlex™ Self-Expanding Stent System, and Protégé® GPS™ Self-Expanding Stent System.
Device
Lead sponsor
Medtronic Endovascular
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 6, 2018 · Synced Jun 26, 2026, 2:35 AM EDT
Not listed Phase 4 Interventional

Effect of Evolocumab in Functional Status and LDL Oxidation of Patients With Peripheral Arterial Disease

NCT04306081
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Evolocumab 140 mg/mL Subcutaneous Injection 1 milliliter (mL) pre-filled injector Pen x 3 for a monthly dose of 420 mg for 6 months., Placebo 1milliliter (mL) Subcutaneous Injection pre-filled injector Pen x 3 monthly for 6 months.
Drug · Other
Lead sponsor
Leonardo Clavijo
Other
Eligibility
40 Years to 85 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 11, 2020 · Synced Jun 26, 2026, 2:35 AM EDT
Completed Phase 2 Interventional Results available

Patients With Intermittent Claudication Injected With ALDH Bright Cells

NCT01774097
View directory record Official record
Conditions
Peripheral Artery Disease, Intermittent Claudication
Interventions
ALD-301, Placebo (vehicle)
Biological
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
40 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
9
States / cities
Stanford, California • Gainesville, Florida • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2017 · Synced Jun 26, 2026, 2:35 AM EDT
Completed Not applicable Interventional Results available

Investigating Superion™ In Spinal Stenosis

NCT00692276
View directory record Official record
Conditions
Lumbar Spinal Stenosis, Intermittent Claudication
Interventions
Superion™ Interspinous Spacer, X-STOP® IPD® Device
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
45 Years and older
Enrollment
391 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
32
States / cities
Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 28 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2020 · Synced Jun 26, 2026, 2:35 AM EDT
Completed Phase 1 Interventional

Technical Development of Cardiovascular Magnetic Resonance Imaging

NCT00064896
View directory record Official record
Conditions
Peripheral Artery Disease
Interventions
MRI
Procedure
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 29, 2017 · Synced Jun 26, 2026, 2:35 AM EDT
Terminated Phase 2 Interventional Results available

Safety, Tolerability and Efficacy of ACZ885 on Leg Artery Structure in Patients With Peripheral Artery Disease

NCT01731990
View directory record Official record
Conditions
Peripheral Artery Disease
Interventions
Canakinumab (ACZ885), Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
8
States / cities
Phoenix, Arizona • Jacksonville, Florida • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Jun 26, 2026, 2:35 AM EDT
Recruiting Phase 2 Interventional

Response to Exercise and Nitric Oxide in PAD

NCT06657976
View directory record Official record
Conditions
Peripheral Artery Disease, Exercise, Intermittent Claudication, Nitric Oxide
Interventions
Supervised Treadmill Exercise, Attention Control, Nitrate-Rich Beetroot Juice + supervised exercise therapy, Placebo + supervised exercise therapy
Behavioral · Combination Product
Lead sponsor
Northwestern University
Other
Eligibility
50 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced Jun 26, 2026, 2:35 AM EDT
Recruiting Not applicable Interventional

Passive Calf Stretching Therapy in Peripheral Artery Disease

NCT06041880
View directory record Official record
Conditions
Peripheral Artery Disease, Claudication, Intermittent
Interventions
Passive calf muscle stretching device
Device
Lead sponsor
Penn State University
Other
Eligibility
40 Years to 85 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Jun 26, 2026, 2:35 AM EDT
Recruiting Phase 3 Interventional

MetfOrmin BenefIts Lower Extremities With Intermittent Claudication

NCT05132439
View directory record Official record
Conditions
Intermittent Claudication
Interventions
Metformin ER, placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
35 Years to 89 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Jun 26, 2026, 2:35 AM EDT
Completed Not applicable Interventional Results available

Tack Optimized Balloon Angioplasty Study of the Tack Endovascular System® in Below the Knee Arteries

NCT02942966
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Tack Endovascular System
Device
Lead sponsor
Philips Clinical & Medical Affairs Global
Industry
Eligibility
18 Years and older
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
37
States / cities
Yuma, Arizona • Fremont, California • Denver, Colorado + 33 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2022 · Synced Jun 26, 2026, 2:35 AM EDT
Completed Phase 1 Interventional

Arterial Imaging of Inflammation and Resolution After Endovascular Surgery

NCT03590769
View directory record Official record
Conditions
Peripheral Arterial Disease, Claudication, Intermittent, Claudication, PAD, SFA - Superficial Femoral Artery Stenosis, Iliac Artery Disease, Vascular Calcification
Interventions
18F-FDG
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
40 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 29, 2020 · Synced Jun 26, 2026, 2:35 AM EDT
Completed Phase 4 Interventional Results available

Intima Versus Adventitia Drug Delivery to Elucidate Mechanisms of Restenosis: Magnetic Resonance Imaging

NCT02807779
View directory record Official record
Conditions
Peripheral Artery Disease, Vascular Disease, Critical Limb Ischemia
Interventions
Dexamethasone infusion, Drug coated balloon, Plain balloon angioplasty
Drug · Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
35 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
2
States / cities
San Francisco, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Jun 26, 2026, 2:35 AM EDT
Not listed Phase 1Phase 2 Interventional

Safety Study of MultiGeneAngio in Patients With Peripheral Arterial Disease (PAD)

NCT00390767
View directory record Official record
Conditions
PAD, Claudication
Interventions
MultiGeneAngio
Biological
Lead sponsor
MultiGene Vascular Systems Ltd.
Industry
Eligibility
50 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2024
U.S. locations
2
States / cities
Ann Arbor, Michigan • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 4, 2015 · Synced Jun 26, 2026, 2:35 AM EDT
Terminated Not applicable Interventional Results available

The Vascular Biology of Dipyridamole in Peripheral Arterial Disease (PAD)

NCT00906035
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Dipyridamole 200mg and Aspirin 25mg bid:, Dipyridamole 200 mg bid, Aspirin 25 mg bid
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 79 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
3
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 4, 2017 · Synced Jun 26, 2026, 2:35 AM EDT
Completed Phase 1Phase 2 Interventional

Safety, Efficacy, and Pharmacokinetics (PK) Study of Trans Sodium Crocetinate (TSC) in Patients With Intermittent Claudication

NCT00725881
View directory record Official record
Conditions
Intermittent Claudication
Interventions
Trans sodium crocetinate (TSC), 0.9% normal saline
Drug
Lead sponsor
Diffusion Pharmaceuticals Inc
Industry
Eligibility
40 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
7
States / cities
Birmingham, Alabama • Santa Rosa, California • Stanford, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2011 · Synced Jun 26, 2026, 2:35 AM EDT
Completed Not applicable Interventional

Best Endovascular vs. Best Surgical Therapy in Patients With Critical Limb Ischemia

NCT02060630
View directory record Official record
Conditions
Critical Limb Ischemia
Interventions
Open surgical revascularization, Endovascular revascularization
Procedure · Device
Lead sponsor
Carelon Research
Other
Eligibility
18 Years and older
Enrollment
1,843 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
144
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 102 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2023 · Synced Jun 26, 2026, 2:35 AM EDT
Completed Phase 3 Interventional

Study of Alfimeprase to Rapidly Dissolve Blood Clots in the Leg and Help Prevent the Need for Surgery on Leg Arteries

NCT00115999
View directory record Official record
Conditions
Arterial Occlusive Diseases
Interventions
alfimeprase
Drug
Lead sponsor
ARCA Biopharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 14, 2008 · Synced Jun 26, 2026, 2:35 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of K-134 for the Treatment of Intermittent Claudication

NCT00783081
View directory record Official record
Conditions
Intermittent Claudication
Interventions
K-134, Cilostazol 100 mg BID, Placebo
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
40 Years and older
Enrollment
387 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
30
States / cities
Tucson, Arizona • Little Rock, Arkansas • Beverly Hills, California + 27 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2012 · Synced Jun 26, 2026, 2:35 AM EDT
Completed Not applicable Interventional

Comparison of Prosthetic Femoropopliteal Bypass Versus Viabahn Endoprosthesis for Treatment of Symptomatic Femoral Artery Occlusive Disease

NCT00693823
View directory record Official record
Conditions
Atherosclerosis, Lower Extremity Ischemia, Claudication, Rest Pain
Interventions
Femoral-popliteal Bypass, Angioplasty and stent placement with Viabahn covered stent-graft(W.L. Gore & Associates, Flagstff, Arizona) of superficial femoral artery
Procedure · Device
Lead sponsor
Texas Vascular Associates
Other
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 8, 2008 · Synced Jun 26, 2026, 2:35 AM EDT
Completed Phase 1 Interventional

Pilot Study of PRT-201 Following Angioplasty in Patients With Peripheral Artery Disease (PAD)

NCT01616290
View directory record Official record
Conditions
Peripheral Artery Disease
Interventions
PRT-201
Drug
Lead sponsor
Proteon Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 10, 2015 · Synced Jun 26, 2026, 2:35 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety of HMR1766 in Patients With Fontaine Stage II Peripheral Arterial Disease

NCT00443287
View directory record Official record
Conditions
Intermittent Claudication
Interventions
ataciguat (HMR1766), placebo, cilostazol
Drug
Lead sponsor
Sanofi
Industry
Eligibility
40 Years and older
Enrollment
553 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 16, 2018 · Synced Jun 26, 2026, 2:35 AM EDT
Completed Phase 3 Interventional Results available

Trial to Evaluate the Safety & Efficacy of the Omnilink Elite™ Peripheral Balloon-Expandable Stent System in Subjects With Atherosclerotic de Novo or Restenotic Lesions in the Native Common Iliac Artery and/or Native External Iliac Artery

NCT01396525
View directory record Official record
Conditions
Peripheral Vascular Disease
Interventions
Omnilink Elite™ Peripheral Balloon-Expandable Stent System
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years to 89 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Santa Clara, California
Source: ClinicalTrials.gov public record
Updated Feb 7, 2016 · Synced Jun 26, 2026, 2:35 AM EDT
Completed Phase 2 Interventional

Mixed Antagonist of Serotonin for Claudication Optimal Therapy

NCT00300339
View directory record Official record
Conditions
Intermittent Claudication
Interventions
SL650472, Clopidogrel
Drug
Lead sponsor
Sanofi
Industry
Eligibility
40 Years and older
Enrollment
599 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 18, 2008 · Synced Jun 26, 2026, 2:35 AM EDT
Terminated No phase listed Observational

FIRE-PAD: Functional Improvement Through Revascularization of the Extremities for Peripheral Arterial Disease

NCT00274157
View directory record Official record
Conditions
Peripheral Vascular Disease
Interventions
Behavior, diet control, smoking cessation, exercize
Behavioral
Lead sponsor
The Cleveland Clinic
Other
Eligibility
40 Years to 85 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 26, 2008 · Synced Jun 26, 2026, 2:35 AM EDT